Goldman Sachs Initiates Coverage On CG Oncology with Neutral Rating, Announces Price Target of $42
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has initiated coverage on CG Oncology (NASDAQ:CGON) with a Neutral rating and set a price target of $42.

February 20, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs initiated coverage on CG Oncology with a Neutral rating and a price target of $42.
The initiation of coverage by a major financial institution like Goldman Sachs generally brings increased attention to a stock. However, the Neutral rating suggests that Goldman Sachs analysts see the stock as fairly valued at its current price, implying limited short-term upside or downside potential. The price target of $42 provides a reference point for investors but does not suggest a significant change from current levels, hence the neutral impact score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100